FDA Approves Telix Brain Cancer Imaging Drug Pixclara

Key points

• FDA approval for Pixclara addresses significant unmet need for glioma imaging.
• Pixclara is the first FDA-approved FET-PET imaging drug for glioma.
• Expands Telix's leadership in diagnostics and targeted radiopharmaceutical therapies.

Full summary

Telix Pharmaceuticals Limited announced that the FDA has approved its New Drug Application for Pixclara, an amino acid PET drug for imaging gliomas. Pixclara is the first FDA-approved FET-PET imaging drug, helping physicians differentiate recurrent or progressive glioma from treatment-related changes. This approval addresses a significant unmet need, as gliomas are the most common form of central nervous system cancer. Pixclara's approval expands Telix's precision medicine business and reinforces its leadership in diagnostics and theranostics.